CDEK
← All drugs Report issue

masitinib

Small moleculeexperimental

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, amyotrophic lateral sclerosis and COVID-19. — Wikipedia

Clinical trial activity

40 trials · 17 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
33
Phase 3
22
Phase 4
0

Earliest trial started Apr 1, 2003 (NCT00112229)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Mol. weight
498.66 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide
  • ab1010
  • ab1010
  • ab1010
  • ab1010
  • ab1010
  • ab1010
  • ab 1010
  • ab-1010
  • ab-1010
  • ab-1010
  • ab-1010
  • kinavet ca-1
  • masatinib
  • masican
  • masitinib
  • masitinib
  • masitinib
  • masitinib
  • masitinib
  • masitinib
  • masitinib
  • masitinib mesilate
  • masitinib mesylate
  • masitinib mesylate
  • masitinib mesylate
  • masitinib mesylate
  • masitinib mesylate
  • masivet

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07174492Phase 3Jan 1, 2026AB Science
NCT05564169Phase 3Nov 15, 2022AB Science, University of Paris
NCT05449444Phase 2Jul 1, 2022AB Science, APHP - Hôpital Necker
NCT05441488Phase 3Jun 28, 2022AB Science, University of Lille
NCT05047783Phase 2Nov 23, 2021AB Science, University Clermont Auvergne
NCT04333108Phase 3Jun 30, 2020AB Science, University of Toulouse
NCT04622865Phase 2Jun 1, 2020AB Science, Aix-Marseille University
NCT03127267Phase 3Sep 1, 2017AB Science
NCT05200169Early Phase 1 (Phase 1)Jul 31, 2017AB Science, Quotient
NCT03771040Phase 3Dec 31, 2016AB Science, University of Oradea
NCT03556956Phase 2/Phase 3 (Phase 3)Jul 15, 2015AB Science, Hôpital Européen Georges-Pompidou
NCT03761225Phase 3Sep 30, 2014AB Science, Polyclinique d'oncologie de Gentilly, Nancy, France
NCT03766295Phase 3Jul 31, 2014AB Science, Centre Hospitalier de Longjumeau, France
NCT02490488Phase 2Apr 1, 2014AB Science
NCT02605044Phase 3Jan 1, 2014AB Science
NCT02009423Phase 3Jan 1, 2014AB Science
NCT02588677Phase 2/Phase 3 (Phase 3)Apr 1, 2013AB Science
NCT01694277Phase 3Apr 1, 2012AB Science
NCT01872598Phase 3Jan 1, 2012AB Science
NCT01433497Phase 2/Phase 3 (Phase 3)Aug 1, 2011AB Science
Showing 20 of 40 trials
Page 1 / 2

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AB ScienceFor profit383832004
University of LilleAcademic/Hospital2012009
Aix-Marseille UniversityAcademic/Hospital1012020
APHP - Hôpital NeckerAcademic/Hospital1012022
Centre Hospitalier de Longjumeau, FranceAcademic/Hospital1012014
Hôpital Européen Georges-PompidouAcademic/Hospital1012015
Ludwig Institute for Cancer ResearchAcademic/Hospital1012003
Northwestern UniversityAcademic/Hospital1112010
Polyclinique d'oncologie de Gentilly, Nancy, FranceAcademic/Hospital1012014
QuotientFor profit1012017
University Clermont AuvergneAcademic/Hospital1012021
University of LausanneAcademic/Hospital1112003
University of LyonAcademic/Hospital1012007
University of Nice Sophia AntipolisAcademic/Hospital1012005
University of OradeaAcademic/Hospital1012016
University of ParisAcademic/Hospital1012022
University of ToulouseAcademic/Hospital1012020
17 organizations
Page 1 / 1